ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
ADENURIC 80 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 80 mg of febuxostat.

Excipient(s) with known effects:
Each tablet contains 76.50 mg of lactose (as monohydrate)

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Pale yellow to yellow, film-coated, capsule shaped tablets, engraved with “80” on one side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications
Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).

ADENURIC is indicated in adults.

4.2 Posology and method of administration

Posology
The recommended oral dose of ADENURIC is 80 mg once daily without regard to food. If serum uric acid is > 6 mg/dL (357 µmol/L) after 2-4 weeks, ADENURIC 120 mg once daily may be considered.

ADENURIC works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357 µmol/L).

Gout flare prophylaxis of at least 6 months is recommended (see section 4.4).

Elderly
No dose adjustment is required in the elderly (see section 5.2).

Renal impairment
The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 mL/min, see section 5.2).
No dose adjustment is necessary in patients with mild or moderate renal impairment.

Hepatic impairment
The efficacy and safety of febuxostat has not been studied in patients with severe hepatic impairment (Child Pugh Class C).
The recommended dose in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment.
Paediatric population
The safety and the efficacy of ADENURIC in children aged below the age of 18 years have not been established. No data are available.

Method of administration
Oral use
ADENURIC should be taken by mouth and can be taken with or without food.

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see also section 4.8).

4.4 Special warnings and precautions for use

Cardio-vascular disorders
Treatment with febuxostat in patients with ischaemic heart disease or congestive heart failure is not recommended.
A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists’ Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section 5.1 for detailed characteristics of the studies). The incidence of investigator-reported cardiovascular APTC events in the combined Phase 3 studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs. In the long-term extension studies the incidences of investigator-reported APTC events were 1.2 and 0.6 events per 100 PYs for febuxostat and allopurinol, respectively. No statistically significant differences were found and no causal relationship with febuxostat was established. Identified risk factors among these patients were a medical history of atherosclerotic disease and/or myocardial infarction, or of congestive heart failure.

Medicinal product allergy / hypersensitivity
Rare reports of serious allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock, have been collected in the post-marketing experience. In most cases, these reactions occurred during the first month of therapy with febuxostat. Some, but not all of these patients reported renal impairment and/or previous hypersensitivity to allopurinol. Severe hypersensitivity reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were associated with fever, haematological, renal or hepatic involvement in some cases.
Patients should be advised of the signs and symptoms and monitored closely for symptoms of allergic/hypersensitivity reactions (see section 4.8). Febuxostat treatment should be immediately stopped if serious allergic/hypersensitivity reactions, including Stevens-Johnson Syndrome, occur since early withdrawal is associated with a better prognosis. If patient has developed allergic/hypersensitivity reactions including Stevens-Johnson Syndrome and acute anaphylactic reaction/shock, febuxostat must not be re-started in this patient at any time.

Acute gouty attacks (gout flare)
Febuxostat treatment should not be started until an acute attack of gout has completely subsided. Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits (see section 4.8 and 5.1). At treatment initiation with febuxostat flare prophylaxis for at least 6 months with an NSAID or colchicine is recommended (see section 4.2).
If a gout flare occurs during febuxostat treatment, it should not be discontinued. The gout flare should be managed concurrently as appropriate for the individual patient. Continuous treatment with febuxostat decreases frequency and intensity of gout flares.
Xanthine deposition
In patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its
treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases,
rise sufficiently to allow deposition in the urinary tract. As there has been no experience with
febuxostat, its use in these populations is not recommended.

Mercaptopurine/azathioprine
Febuxostat use is not recommended in patients concomitantly treated with
mercaptopurine/azathioprine as inhibition of xanthine oxidase by febuxostat may cause increased
plasma concentrations of mercaptopurine/azathioprine that could result in severe toxicity. No
interaction studies have been performed in humans.
Where the combination cannot be avoided, a reduction of the dose of mercaptopurine/azathioprine is
recommended. Based on modelling and simulation analysis of data from a pre-clinical study in rats,
when coadministered with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to
the 20% or less of the previously prescribed dose in order to avoid possible haematological effects (see
section 4.4 and 5.3).
The patients should be closely monitored and the dose of mercaptopurine/azathioprine should be
subsequently adjusted based on the evaluation of the therapeutic response and the onset of eventual
toxic effects.

Organ transplant recipients
As there has been no experience in organ transplant recipients, the use of febuxostat in such patients is
not recommended (see section 5.1).

Theophylline
Co-administration of febuxostat 80 mg and theophylline 400mg single dose in healthy subjects
showed absence of any pharmacokinetic interaction (see section 4.5). Febuxostat 80 mg can be used in
patients concomitantly treated with theophylline without risk of increasing theophylline plasma levels.
No data is available for febuxostat 120 mg.

Liver disorders
During the combined phase 3 clinical studies, mild liver function test abnormalities were observed in
patients treated with febuxostat (5.0%). Liver function test is recommended prior to the initiation of
therapy with febuxostat and periodically thereafter based on clinical judgment (see section 5.1).

Thyroid disorders
Increased TSH values (>5.5 µIU/mL) were observed in patients on long-term treatment with
febuxostat (5.5%) in the long term open label extension studies. Caution is required when febuxostat is
used in patients with alteration of thyroid function (see section 5.1).

Lactose
Febuxostat tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the
Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Mercaptopurine/azathioprine
On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not
recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of these
drugs leading to toxicity. Drug interaction studies of febuxostat with drugs (except theophylline) that
are metabolized by XO have not been performed in humans.
Modelling and simulation analysis of data from a pre-clinical study in rats indicates that, in case of
concomitant administration with febuxostat, the dose of mercaptopurine/azathioprine should be
reduced to 20% or less of the previously prescribed dose (see section 4.4 and 5.3)
Drug interaction studies of febuxostat with other cytotoxic chemotherapy have not been conducted. No data is available regarding the safety of febuxostat during other cytotoxic therapy.

**Rosiglitazone/CYP2C8 substrates**
Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in healthy subjects, coadministration of 120 mg febuxostat QD with a single 4 mg oral dose of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme inhibitor in vivo. Thus, co-administration of febuxostat with rosiglitazone or other CYP2C8 substrates is not expected to require any dose adjustment for those compounds.

**Theophylline**
An interaction study in healthy subjects has been performed with febuxostat to evaluate whether the inhibition of XO may cause an increase in the theophylline circulating levels as reported with other XO inhibitors. The results of the study showed that the co-administration of febuxostat 80 mg QD with theophylline 400 mg single dose has no effect on the pharmacokinetics or safety of theophylline. Therefore no special caution is advised when febuxostat 80 mg and theophylline are given concomitantly. No data is available for febuxostat 120 mg.

**Naproxen and other inhibitors of glucuronidation**
Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit glucuronidation, such as NSAIDs and probenecid, could in theory affect the elimination of febuxostat. In healthy subjects concomitant use of febuxostat and naproxen 250 mg twice daily was associated with an increase in febuxostat exposure (C$_{max}$ 28%, AUC 41% and t$_{1/2}$ 26%). In clinical studies the use of naproxen or other NSAIDs/Cox-2 inhibitors was not related to any clinically significant increase in adverse events.

Febuxostat can be co-administered with naproxen with no dose adjustment of febuxostat or naproxen being necessary.

**Inducers of glucuronidation**
Potent inducers of UGT enzymes might possibly lead to increased metabolism and decreased efficacy of febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation. Conversely, cessation of treatment of an inducer might lead to increased plasma levels of febuxostat.

**Colchicine/indometacin/hydrochlorothiazide/warfarin**
Febuxostat can be co-administered with colchicine or indomethacin with no dose adjustment of febuxostat or the co-administered active substance being necessary.

No dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide.

No dose adjustment is necessary for warfarin when administered with febuxostat. Administration of febuxostat (80 mg or 120 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy subjects. INR and Factor VII activity were also not affected by the co-administration of febuxostat.

**Desipramine/CYP2D6 substrates**
Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in healthy subjects, 120 mg ADENURIC QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme in vivo. Thus, co-administration of febuxostat with other CYP2D6 substrates is not expected to require any dose adjustment for those compounds.

**Antacids**
Concomitant ingestion of an antacid containing magnesium hydroxide and aluminium hydroxide has been shown to delay absorption of febuxostat (approximately 1 hour) and to cause a 32% decrease in \( C_{max} \), but no significant change in AUC was observed. Therefore, febuxostat may be taken without regard to antacid use.

**4.6 Fertility, pregnancy and lactation**

**Pregnancy**

Data on a very limited number of exposed pregnancies have not indicated any adverse effects of febuxostat on pregnancy or on the health of the foetus/new born child. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development or parturition (see section 5.3). The potential risk for human is unknown. Febuxostat should not be used during pregnancy.

**Breastfeeding**

It is unknown whether febuxostat is excreted in human breast milk. Animal studies have shown excretion of this active substance in breast milk and an impaired development of suckling pups. A risk to a suckling infant cannot be excluded. Febuxostat should not be used while breastfeeding.

**Fertility**

In animals, reproduction studies up to 48 mg/kg/day showed no dose-dependent adverse effects on fertility (see section 5.3). The effect of ADENURIC on human fertility is unknown.

**4.7 Effects on ability to drive and use machines**

Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of Febuxostat. Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that ADENURIC does not adversely affect performance.

**4.8 Undesirable effects**

**Summary of the safety profile**

The most commonly reported adverse reactions in clinical trials (4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema. These adverse reactions were mostly mild or moderate in severity. Rare serious hypersensitivity reactions to febuxostat, some of which were associated to systemic symptoms, have occurred in the post-marketing experience.

**Tabulated list of adverse reactions**

Common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100) and rare (≥1/10,000 to <1/1,000) adverse reactions occurring in patients treated with febuxostat are listed below.

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

**Table 1: Adverse reactions in combined phase 3, long-term extension studies and post-marketing experience**

<table>
<thead>
<tr>
<th>Blood and lymphatic system disorders</th>
<th>Rare</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pancytopenia, thrombocytopenia, agranulocytosis*</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Anaphylactic reaction*, drug hypersensitivity*</td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Blood thyroid stimulating hormone increased</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Blurred vision</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Common***</td>
</tr>
<tr>
<td></td>
<td>Gout flares</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
</tr>
<tr>
<td>Domain</td>
<td>Condition</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Diabetes mellitus, hyperlipidemia</td>
<td>Decrease appetite, weight increase</td>
</tr>
<tr>
<td></td>
<td>Weight decrease, increase appetite, anorexia</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Weight decrease, increase appetite</td>
</tr>
<tr>
<td></td>
<td>Libido decreased, insomnia</td>
</tr>
<tr>
<td></td>
<td>Nervousness</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache</td>
</tr>
<tr>
<td></td>
<td>Dizziness, paraesthesia, hemiparesis, somnolence, altered taste, hyponaesthesia, hyposmia</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>Weight decrease, increase appetite</td>
</tr>
<tr>
<td></td>
<td>Libido decreased, insomnia</td>
</tr>
<tr>
<td></td>
<td>Nervousness</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Heart rhythm irritation, palpitations</td>
</tr>
<tr>
<td></td>
<td>ECG abnormal</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Hypertension, flushing, hot flush</td>
</tr>
<tr>
<td>Respiratory system disorders</td>
<td>Dyspnoea, bronchitis, upper respiratory tract infection, cough</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Diarrhoea**, nausea</td>
</tr>
<tr>
<td></td>
<td>Abdominal pain, abdominal distension, gastro-oesophageal reflux disease, vomiting, dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort</td>
</tr>
<tr>
<td></td>
<td>Pancreatitis, mouth ulceration</td>
</tr>
<tr>
<td>Hepato-biliary disorders</td>
<td>Liver function abnormalities**</td>
</tr>
<tr>
<td></td>
<td>Cholelithiasis</td>
</tr>
<tr>
<td></td>
<td>Hepatitis, jaundice*, liver injury*</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Rash (including various types of rash reported with lower frequencies, see below)</td>
</tr>
<tr>
<td></td>
<td>Dermatitis, urticaria, pruritus, skin discolouration, skin lesion, petechiae, rash macular, rash maculopapular, rash papular</td>
</tr>
<tr>
<td></td>
<td>Toxic epidermal necrolysis*, Stevens-Johnson Syndrome*, angioedema*, drug reaction with eosinophilia and systemic symptoms*, generalized rash (serious)<em>, erythema, exfoliative rash, rash follicular, rash vesicular, rash pustular, rash pruritic</em>, rash erythematous, rash morbilliform, alopecia, hyperhidrosis</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Arthralgia, arthritis, myalgia, musculoskeletal pain, muscle weakness, muscle spasm, muscle tightness, bursitis</td>
</tr>
<tr>
<td></td>
<td>Rhabdomyolysis*, joint stiffness, musculoskeletal stiffness</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Renal failure, nephrolithiasis, haematuria, pollakiuria, proteinuria</td>
</tr>
<tr>
<td></td>
<td>Tubulointerstitial nephritis*, micturition urgency</td>
</tr>
<tr>
<td>Reproductive system and breast</td>
<td>Renal failure, nephrolithiasis, haematuria, pollakiuria, proteinuria</td>
</tr>
</tbody>
</table>

* Rare
** Common

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>General disorders and administration site conditions</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Oedema</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Fatigue, chest pain, chest discomfort</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Thirst</td>
</tr>
<tr>
<td>Investigations</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Blood amylase increase, platelet count decrease, WBC decrease,</td>
</tr>
<tr>
<td></td>
<td>lymphocyte count decrease, blood creatine increase, blood</td>
</tr>
<tr>
<td></td>
<td>creatinine increase, haemoglobin decrease, blood urea increase,</td>
</tr>
<tr>
<td></td>
<td>blood triglycerides increase, blood cholesterol increase,</td>
</tr>
<tr>
<td></td>
<td>haematocrit decrease, blood lactate dehydrogenase increased,</td>
</tr>
<tr>
<td></td>
<td>blood potassium increase</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Blood glucose increase, activated partial thromboplastin time prolonged,</td>
</tr>
<tr>
<td></td>
<td>red blood cell count decrease, blood alkaline</td>
</tr>
<tr>
<td></td>
<td>phosphatase increase, blood creatine phosphokinase increase*</td>
</tr>
</tbody>
</table>

* Adverse reactions coming from post-marketing experience
** Treatment-emergent non-infective diarrhoea and abnormal liver function tests in the combined Phase 3 studies are more frequent in patients concomitantly treated with colchicine.
*** See section 5.1 for incidences of gout flares in the individual Phase 3 randomized controlled studies.

Description of selected adverse reactions

Rare serious hypersensitivity reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal necrolysis and anaphylactic reaction/shock, have occurred in the post-marketing experience. Stevens-Johnson Syndrome and Toxic epidermal necrolysis are characterised by progressive skin rashes associated with blisters or mucosal lesions and eye irritation. Hypersensitivity reactions to febuxostat can be associated to the following symptoms: skin reactions characterised by infiltrated maculopapular eruption, generalised or exfoliative rashes, but also skin lesions, facial oedema, fever, haematologic abnormalities such as thrombocytopenia and eosinophilia, and single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis) (see section 4.4).

Gout flares were commonly observed soon after the start of treatment and during the first months. Thereafter, the frequency of gout flare decreases in a time-dependent manner. Gout flare prophylaxis is recommended (see section 4.2 and 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Patients with an overdose should be managed by symptomatic and supportive care.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antigout preparation, preparations inhibiting uric acid production, ATC code: M04AA03

Mechanism of action
Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. Febuxostat is a potent, non-purine selective inhibitor of XO (NP-SIXO) with an in vitro inhibition Ki value less than one nanomolar. Febuxostat has been shown to potently inhibit both the oxidized and reduced forms of XO. At therapeutic concentrations febuxostat does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.

Clinical efficacy and safety
The efficacy of ADENURIC was demonstrated in three Phase 3 pivotal studies (the two pivotal APEX and FACT studies, and the additional CONFIRMS study described below) that were conducted in 4101 patients with hyperuricaemia and gout. In each phase 3 pivotal study, ADENURIC demonstrated superior ability to lower and maintain serum uric acid levels compared to allopurinol. The primary efficacy endpoint in the APEX and FACT studies was the proportion of patients whose last 3 monthly serum uric acid levels were < 6.0 mg/dL (357 µmol/L). In the additional phase 3 CONFIRMS study, for which results became available after the marketing authorisation for ADENURIC was first issued, the primary efficacy endpoint was the proportion of patients whose serum urate level was < 6.0 mg/dL at the final visit. No patients with organ transplant have been included in these studies (see section 4.2).

APEX Study: The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study. One thousand and seventy-two (1072) patients were randomized: placebo (n=134), ADENURIC 80 mg QD (n=267), ADENURIC 120 mg QD (n=269), ADENURIC 240 mg QD (n=134) or allopurinol (300 mg QD [n=258] for patients with a baseline serum creatinine ≤ 1.5 mg/dL or 100 mg QD [n=10] for patients with a baseline serum creatinine >1.5 mg/dL and ≤2.0 mg/dL). Two hundred and forty mg febuxostat (2 times the recommended highest dose) was used as a safety evaluation dose.

The APEX study showed statistically significant superiority of both the ADENURIC 80 mg QD and the ADENURIC 120 mg QD treatment arms versus the conventionally used doses of allopurinol 300 mg (n = 258)/100 mg (n = 10) treatment arm in reducing the sUA below 6 mg/dL (357 µmol/L) (see Table 2 and Figure 1).

FACT Study: The Febuxostat Allopurinol Controlled Trial (FACT) Study was a Phase 3, randomized, double-blind, multicenter, 52-week study. Seven hundred sixty (760) patients were randomized: ADENURIC 80 mg QD (n=256), ADENURIC 120 mg QD (n=251), or allopurinol 300 mg QD (n=253).

The FACT study showed the statistically significant superiority of both ADENURIC 80 mg and ADENURIC 120 mg QD treatment arms versus the conventionally used dose of allopurinol 300 mg treatment arm in reducing and maintaining sUA below 6 mg/dL (357 µmol/L).
Table 2 summarises the primary efficacy endpoint results:

### Table 2
Proportion of Patients with Serum Uric Acid Levels <6.0 mg/dL (357 µmol/L) Last Three Monthly Visits

<table>
<thead>
<tr>
<th>Study</th>
<th>ADENURIC 80 mg QD</th>
<th>ADENURIC 120 mg QD</th>
<th>Allopurinol 300 / 100 mg QD&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>APEX (28 weeks)</td>
<td>48%&lt;sup&gt;*&lt;/sup&gt; (n=262)</td>
<td>65%&lt;sup&gt;*,#&lt;/sup&gt; (n=269)</td>
<td>22% (n=268)</td>
</tr>
<tr>
<td>FACT (52 weeks)</td>
<td>53% (n=255)</td>
<td>62% (n=250)</td>
<td>21% (n=251)</td>
</tr>
<tr>
<td>Combined Results</td>
<td>51%&lt;sup&gt;*&lt;/sup&gt; (n=517)</td>
<td>63%&lt;sup&gt;*,#&lt;/sup&gt; (n=519)</td>
<td>22% (n=519)</td>
</tr>
</tbody>
</table>

<sup>1</sup>results from subjects receiving either 100 mg QD (n=10: patients with serum creatinine >1.5 and ≤2.0 mg/dL) or 300 mg QD (n=509) were pooled for analyses.  
*p < 0.001 vs allopurinol, # p < 0.001 vs 80 mg

The ability of ADENURIC to lower serum uric acid levels was prompt and persistent. Reduction in serum uric acid level to <6.0 mg/dL (357 µmol/L) was noted by the Week 2 visit and was maintained throughout treatment. The mean serum uric acid levels over time for each treatment group from the two pivotal Phase 3 studies are shown in Figure 1.

**Figure 1 Mean Serum Uric Acid Levels in Combined Pivotal Phase 3 Studies**

Note: 509 patients received allopurinol 300 mg QD; 10 patients with serum creatinine >1.5 and ≤2.0 mg/dL were dosed with 100 mg QD. (10 patients out of 268 in APEX study).

240 mg febuxostat was used to evaluate the safety of febuxostat at twice the recommended highest dose.

CONFIRMS Study: The CONFIRMS study was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and efficacy of febuxostat 40 mg and 80 mg, in comparison with allopurinol.
300 mg or 200 mg, in patients with gout and hyperuricaemia. Two thousand and two hundred-sixty nine (2269) patients were randomized: ADENURIC 40 mg QD (n=757), ADENURIC 80 mg QD (n=756), or allopurinol 300/200 mg QD (n=756). At least 65% of the patients had mild-moderate renal impairment (with creatinine clearance of 30-89 mL/min). Prophylaxis against gout flares was obligatory over the 26-week period.

The proportion of patients with serum urate levels of < 6.0 mg/dL (357 µmol/L) at the final visit, was 45% for 40 mg febuxostat, 67% for febuxostat 80 mg and 42% for allopurinol 300/200 mg, respectively.

Primary endpoint in the sub-group of patients with renal impairment
The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine > 1.5 mg/dL and ≤2.0 mg/dL). For renally impaired subjects who were randomized to allopurinol, the dose was capped at 100 mg QD. ADENURIC achieved the primary efficacy endpoint in 44% (80 mg QD), 45% (120 mg QD), and 60% (240 mg QD) of patients compared to 0% in the allopurinol 100 mg QD and placebo groups.

There were no clinically significant differences in the percent decrease in serum uric acid concentration in healthy subjects irrespective of their renal function (58% in the normal renal function group and 55% in the severe renal dysfunction group).

An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study, and showed that febuxostat was significantly more efficacious in lowering serum urate levels to < 6 mg/dL, compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65% of patients studied).

Primary endpoint in the sub group of patients with sUA ≥ 10 mg/dL
Approximately 40% of patients (combined APEX and FACT) had a baseline sUA of ≥ 10 mg/dL. In this subgroup ADENURIC achieved the primary efficacy endpoint (sUA < 6.0 mg/dL at the last 3 visits) in 41% (80 mg QD), 48% (120 mg QD), and 66% (240 mg QD) of patients compared to 9% in the allopurinol 300 mg/100 mg QD and 0% in the placebo groups.

In the CONFIRMS study, the proportion of patients achieving the primary efficacy endpoint (sUA < 6.0 mg/dL at the final visit) for patients with a baseline serum urate level of ≥ 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD 49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively.

Clinical Outcomes: proportion of patients requiring treatment for a gout flare
APEX study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for gout flare compared to febuxostat 80 mg (28%), allopurinol 300 mg (23%) and placebo (20%). Flares increased following the prophylaxis period and gradually decreased over time. Between 46% and 55% of subjects received treatment for gout flares from Week 8 and Week 28. Gout flares during the last 4 weeks of the study (Weeks 24-28) were observed in 15% (febuxostat 80, 120 mg), 14% (allopurinol 300 mg) and 20% (placebo) of subjects.

FACT study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for a gout flare compared to both the febuxostat 80 mg (22%) and allopurinol 300 mg (21%) treatment groups. After the 8-week prophylaxis period, the incidences of flares increased and gradually decreased over time (64% and 70% of subjects received treatment for gout flares from Week 8-52). Gout flares during the last 4 weeks of the study (Weeks 49-52) were observed in 6-8% (febuxostat 80 mg, 120 mg) and 11% (allopurinol 300 mg) of subjects.

The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level <6.0 mg/dL, <5.0 mg/dL, or <4.0 mg/dL compared to the group that achieved an average post-baseline serum urate level ≥6.0 mg/dL during the last 32 weeks of the treatment period (Week 20-Week 24 to Week 49 - 52 intervals).
During the CONFIRMS study, the percentages of patients who required treatment for gout flares (Day 1 through Month 6) were 31% and 25% for the febuxostat 80 mg and allopurinol groups, respectively. No difference in the proportion of patients requiring treatment for gout flares was observed between the febuxostat 80 mg and 40 mg groups.

**Long-term, open label extension Studies**

EXCEL Study (C02-021): The Excel study was a three years Phase 3, open label, multicenter, randomised, allopurinol-controlled, safety extension study for patients who had completed the pivotal Phase 3 studies (APEX or FACT). A total of 1,086 patients were enrolled: ADENURIC 80 mg QD (n=649), Adenuric 120 mg QD (n=292) and allopurinol 300/100 mg QD (n=145). About 69% of patients required no treatment change to achieve a final stable treatment. Patients who had 3 consecutive sUA levels >6.0 mg/dL were withdrawn. Serum urate levels were maintained over time (i.e. 91% and 93% of patients on initial treatment with febuxostat 80 mg and 120 mg, respectively, had sUA <6 mg/dL at Month 36).

Three years data showed a decrease in the incidence of gout flares with less than 4% of patients requiring treatment for a flare (i.e. more than 96% of patients did not require treatment for a flare) at Month 16-24 and at Month 30-36.

46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.

FOCUS Study (TMX-01-005) was a 5 years Phase 2, open-label, multicenter, safety extension study for patients who had completed the febuxostat 4 weeks of double blind dosing in study TMX-00-004. 116 patients were enrolled and received initially febuxostat 80 mg QD. 62% of patients required no dose adjustment to maintain sUA <6 mg/dL and 38% of patients required a dose adjustment to achieve a final stable dose.

The proportion of patients with serum urate levels of <6.0 mg/dL (357 µmol/L) at the final visit was greater than 80% (81-100%) at each febuxostat dose.

During the phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). These rates were similar to the rates reported on allopurinol (4.2%) (see section 4.4). Increased TSH values (>5.5 µIU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) and patients with allopurinol (5.8%) in the long term open label extension studies (see section 4.4).

### 5.2 Pharmacokinetic properties

In healthy subjects, maximum plasma concentrations (C\text{max}) and area under the plasma concentration time curve (AUC) of febuxostat increased in a dose proportional manner following single and multiple doses of 10 mg to 120 mg. For doses between 120 mg and 300 mg, a greater than dose proportional increase in AUC is observed for febuxostat. There is no appreciable accumulation when doses of 10 mg to 240 mg are administered every 24 hours. Febuxostat has an apparent mean terminal elimination half-life (t\text{1/2}) of approximately 5 to 8 hours.

Population pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with hyperuricaemia and gout, treated with ADENURIC 40-240 mg QD. In general, febuxostat pharmacokinetic parameters estimated by these analyses are consistent with those obtained from healthy subjects, indicating that healthy subjects are representative for pharmacokinetic/pharmacodynamic assessment in the patient population with gout.

**Absorption**

Febuxostat is rapidly (t\text{max} of 1.0-1.5 h) and well absorbed (at least 84%). After single or multiple oral 80 and 120 mg once daily doses, C\text{max} is approximately 2.8-3.2 µg/mL, and 5.0-5.3 µg/mL, respectively. Absolute bioavailability of the febuxostat tablet formulation has not been studied.
Following multiple oral 80 mg once daily doses or a single 120 mg dose with a high fat meal, there was a 49% and 38% decrease in Cmax and a 18% and 16% decrease in AUC, respectively. However, no clinically significant change in the percent decrease in serum uric acid concentration was observed where tested (80 mg multiple dose). Thus, ADENURIC may be taken without regard to food.

Distribution
The apparent steady state volume of distribution (Vss/F) of febuxostat ranges from 29 to 75 L after oral doses of 10-300 mg. The plasma protein binding of febuxostat is approximately 99.2%, (primarily to albumin), and is constant over the concentration range achieved with 80 and 120 mg doses. Plasma protein binding of the active metabolites ranges from about 82% to 91%.

Biotransformation
Febuxostat is extensively metabolized by conjugation via uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system and oxidation via the cytochrome P450 (CYP) system. Four pharmacologically active hydroxyl metabolites have been identified, of which three occur in plasma of humans. In vitro studies with human liver microsomes showed that those oxidative metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was formed mainly by UGT 1A1, 1A8, and 1A9.

Elimination
Febuxostat is eliminated by both hepatic and renal pathways. Following an 80 mg oral dose of 14C-labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%). In addition to the urinary excretion, approximately 45% of the dose was recovered in the faeces as the unchanged febuxostat (12%), the acyl glucuronide of the active substance (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%).

Renal impairment
Following multiple doses of 80 mg of ADENURIC in patients with mild, moderate or severe renal impairment, the Cmax of febuxostat did not change, relative to subjects with normal renal function. The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5 µg.h/mL in the normal renal function group to 13.2 µg.h/mL in the severe renal dysfunction group. The Cmax and AUC of active metabolites increased up to 2- and 4-fold, respectively. However, no dose adjustment is necessary in patients with mild or moderate renal impairment.

Hepatic impairment
Following multiple doses of 80 mg of ADENURIC in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, the Cmax and AUC of febuxostat and its metabolites did not change significantly compared to subjects with normal hepatic function. No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C).

Age
There were no significant changes observed in AUC of febuxostat or its metabolites following multiple oral doses of ADENURIC in elderly as compared to younger healthy subjects.

Gender
Following multiple oral doses of ADENURIC, the Cmax and AUC were 24% and 12% higher in females than in males, respectively. However, weight-corrected Cmax and AUC were similar between the genders. No dose adjustment is needed based on gender.

5.3 Preclinical safety data
Effects in non-clinical studies were generally observed at exposures in excess of the maximum human exposure.
Pharmacokinetic modelling and simulation of rat data suggests that, when co-administered with febuxostat, the clinical dose of mercaptopurine/azathioprine should be reduced to 20% or less of the previously prescribed dose in order to avoid possible haematological effects (see section 4.4 and 4.5).

Carcinogenesis, mutagenesis, impairment of fertility
In male rats, a statistically significant increase in urinary bladder tumours (transitional cell papilloma and carcinoma) was found only in association with xanthine calculi in the high dose group, at approximately 11 times human exposure. There was no significant increase in any other tumour type in either male or female mice or rats. These findings are considered a consequence of species specific purine metabolism and urine composition and of no relevance to clinical use.

A standard battery of test for genotoxicity did not reveal any biologically relevant genotoxic effects for febuxostat.

Febuxostat at oral doses up to 48 mg/kg/day was found to have no effect on fertility and reproductive performance of male and female rats.

There was no evidence of impaired fertility, teratogenic effects, or harm to the foetus due to febuxostat. There was high dose maternal toxicity accompanied by a reduction in weaning index and reduced development of offspring in rats at approximately 4.3 times human exposure. Teratology studies, performed in pregnant rats at approximately 4.3 times and pregnant rabbits at approximately 13 times human exposure did not reveal any teratogenic effects.

### 6. PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

**Tablet core**
- Lactose monohydrate
- Microcrystalline cellulose
- Magnesium stearate
- Hydroxypropylcellulose
- Croscarmellose sodium
- Silica, colloidal hydrated

**Tablet coating**
- Opadry II, Yellow, 85F42129 containing:
  - Polyvinyl alcohol
  - Titanium dioxide (E171)
  - Macrogols 3350
  - Talc
  - Iron oxide yellow (E172)

#### 6.2 Incompatibilities

Not applicable.

#### 6.3 Shelf life

3 years.

#### 6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

#### 6.5 Nature and contents of container
Clear (Aclar/PVC/Aluminium or PVC/PE/PVDC/Aluminium) blister of 14 tablets.

ADENURIC 80 mg is available in pack sizes of 14, 28, 42, 56, 84 and 98 film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare, L-1611 Luxembourg
Luxembourg

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/447/001
EU/1/08/447/002
EU/1/08/447/005
EU/1/08/447/006
EU/1/08/447/007
EU/1/08/447/008
EU/1/08/447/013
EU/1/08/447/014
EU/1/08/447/015
EU/1/08/447/016
EU/1/08/447/017
EU/1/08/447/018

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 April 2008
Date of latest renewal: 20 December 2012

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
1. NAME OF THE MEDICINAL PRODUCT
ADENURIC 120 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 120 mg of febuxostat.

Excipient(s) with known effects:
Each tablet contains 114.75 mg of lactose (as monohydrate)

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Film-coated tablet (tablets).
Pale yellow to yellow, film-coated, capsule shaped tablets, engraved with “120” on one side

4. CLINICAL PARTICULARS
4.1 Therapeutic indications
ADENURIC is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).

ADENURIC is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).

ADENURIC is indicated in adults.

4.2 Posology and method of administration

Posology
Gout: The recommended oral dose of ADENURIC is 80 mg once daily without regard to food. If serum uric acid is > 6 mg/dL (357 µmol/L) after 2-4 weeks, ADENURIC 120 mg once daily may be considered.

ADENURIC works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357 µmol/L).

Gout flare prophylaxis of at least 6 months is recommended (see section 4.4).

Tumor Lysis Syndrome: The recommended oral dose of ADENURIC is 120 mg once daily without regard to food. ADENURIC should be started two days before the beginning of cytotoxic therapy and continued for a minimum of 7 days; however treatment may be prolonged up to 9 days according to chemotherapy duration as per clinical judgment.

Elderly
No dose adjustment is required in the elderly (see section 5.2).
**Renal impairment**
The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 mL/min, see section 5.2). No dose adjustment is necessary in patients with mild or moderate renal impairment.

**Hepatic impairment**
The efficacy and safety of febuxostat has not been studied in patients with severe hepatic impairment (Child Pugh Class C). Gout: The recommended dose in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment.

Tumour Lysis Syndrome: in the pivotal Phase III trial (FLORENCE) only subjects with severe hepatic insufficiency were excluded from trial participation. No dose adjustment was required for enrolled patients on the basis of hepatic function.

**Paediatric population**
The safety and the efficacy of ADENURIC in children aged below the age of 18 years have not been established. No data are available.

**Method of administration**
Oral use
ADENURIC should be taken by mouth and can be taken with or without food.

### 4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see also section 4.8).

### 4.4 Special warnings and precautions for use

**Cardio-vascular disorders**

**Treatment of chronic hyperuricaemia**
Treatment with febuxostat in patients with ischaemic heart disease or congestive heart failure is not recommended. A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists’ Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section 5.1 for detailed characteristics of the studies). The incidence of investigator-reported cardiovascular APTC events in the combined Phase 3 studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs. In the long-term extension studies the incidences of investigator-reported APTC events were 1.2 and 0.6 events per 100 PYs for febuxostat and allopurinol, respectively. No statistically significant differences were found and no causal relationship with febuxostat was established. Identified risk factors among these patients were a medical history of atherosclerotic disease and/or myocardial infarction, or of congestive heart failure.

**Prevention and treatment of hyperuricaemia in patients at risk of TLS**

Patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome treated with ADENURIC should be under cardiac monitoring as clinically appropriate.

**Medicinal product allergy / hypersensitivity**

Rare reports of serious allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock, have been collected in the post-marketing experience. In most cases, these reactions occurred during the first month of therapy with febuxostat. Some, but not all of these patients reported renal impairment and/or previous hypersensitivity to allopurinol. Severe hypersensitivity reactions, including Drug Reaction with
Eosinophilia and Systemic Symptoms (DRESS) were associated with fever, haematological, renal or hepatic involvement in some cases. Patients should be advised of the signs and symptoms and monitored closely for symptoms of allergic/hypersensitivity reactions (see section 4.8). Febuxostat treatment should be immediately stopped if serious allergic/hypersensitivity reactions, including Stevens-Johnson Syndrome, occur since early withdrawal is associated with a better prognosis. If patient has developed allergic/hypersensitivity reactions including Stevens-Johnson Syndrome and acute anaphylactic reaction/shock, febuxostat must not be re-started in this patient at any time.

**Acute gouty attacks (gout flare)**
Febuxostat treatment should not be started until an acute attack of gout has completely subsided. Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits (see sections 4.8 and 5.1). At treatment initiation with febuxostat flare prophylaxis for at least 6 months with an NSAID or colchicine is recommended (see section 4.2).
If a gout flare occurs during febuxostat treatment, it should not be discontinued. The gout flare should be managed concurrently as appropriate for the individual patient. Continuous treatment with febuxostat decreases frequency and intensity of gout flares.

**Xanthine deposition**
In patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. This has not been observed in the pivotal clinical study with ADENURIC in the Tumor Lysis Syndrome. As there has been no experience with febuxostat, its use in patients with Lesch-Nyhan Syndrome is not recommended.

**Mercaptopurine/azathioprine**
Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine as inhibition of xanthine oxidase by febuxostat may cause increased plasma concentrations of mercaptopurine/azathioprine that could result in severe toxicity. No interaction studies have been performed in humans.
Where the combination cannot be avoided, a reduction of the dose of mercaptopurine/azathioprine is recommended. Based on modelling and simulation analysis of data from a pre-clinical study in rats, when coadministered with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to the 20% or less of the previously prescribed dose in order to avoid possible haematological effects (see section 4.5 and 5.3).
The patients should be closely monitored and the dose of mercaptopurine/azathioprine should be subsequently adjusted based on the evaluation of the therapeutic response and the onset of eventual toxic effects.

**Organ transplant recipients**
As there has been no experience in organ transplant recipients, the use of febuxostat in such patients is not recommended (see section 5.1).

**Theophylline**
Co-administration of febuxostat 80 mg and theophylline 400mg single dose in healthy subjects showed absence of any pharmacokinetic interaction (see section 4.5). Febuxostat 80 mg can be used in patients concomitantly treated with theophylline without risk of increasing theophylline plasma levels. No data is available for febuxostat 120 mg.

**Liver disorders**
During the combined phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). Liver function test is recommended prior to the initiation of therapy with febuxostat and periodically thereafter based on clinical judgment (see section 5.1).

**Thyroid disorders**
Increased TSH values (>5.5 µIU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) in the long term open label extension studies. Caution is required when febuxostat is used in patients with alteration of thyroid function (see section 5.1).

**Lactose**
Febuxostat tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

### 4.5 Interaction with other medicinal products and other forms of interaction

**Mercaptopurine/azathioprine**
On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of these drugs leading to toxicity. Drug interaction studies of febuxostat with drugs (except theophylline) that are metabolized by XO have not been performed in humans. Modelling and simulation analysis of data from a pre-clinical study in rats indicates that, in case of concomitant administration with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to the 20% or less of the previously prescribed dose (see section 4.4 and 5.3).

Drug interaction studies of febuxostat with other cytotoxic chemotherapy have not been conducted. In the Tumor Lysis Syndrome pivotal trial febuxostat 120 mg daily was administered to patients undergoing several chemotherapy regimens, including monoclonal antibodies. However, drug-drug and drug-disease interactions were not explored during this study. Therefore, possible interactions with any concomitantly administered cytotoxic drug cannot be ruled out.

**Rosiglitazone/CYP2C8 substrates**
Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in healthy subjects, coadministration of 120 mg febuxostat QD with a single 4 mg oral dose of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme inhibitor in vivo. Thus, co-administration of febuxostat with rosiglitazone or other CYP2C8 substrates is not expected to require any dose adjustment for those compounds.

**Theophylline**
An interaction study in healthy subjects has been performed with febuxostat to evaluate whether the inhibition of XO may cause an increase in the theophylline circulating levels as reported with other XO inhibitors. The results of the study showed that the co-administration of febuxostat 80 mg QD with theophylline 400 mg single dose has no effect on the pharmacokinetics or safety of theophylline. Therefore no special caution is advised when febuxostat 80 mg and theophylline are given concomitantly. No data is available for febuxostat 120 mg.

**Naproxen and other inhibitors of glucuronidation**
Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit glucuronidation, such as NSAIDs and probenecid, could in theory affect the elimination of febuxostat. In healthy subjects concomitant use of febuxostat and naproxen 250mg twice daily was associated with an increase in febuxostat exposure (C\text{max} 28%, AUC 41% and t\text{1/2} 26%). In clinical studies the use of naproxen or other NSAIDs/Cox-2 inhibitors was not related to any clinically significant increase in adverse events.

Febuxostat can be co-administered with naproxen with no dose adjustment of febuxostat or naproxen being necessary.

**Inducers of glucuronidation**
Potent inducers of UGT enzymes might possibly lead to increased metabolism and decreased efficacy of febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation. Conversely, cessation of treatment of an inducer might lead to increased plasma levels of febuxostat.
Colchicine/indometacin/hydrochlorothiazide/warfarin
Febuxostat can be co-administered with colchicine or indomethacin with no dose adjustment of febuxostat or the co-administered active substance being necessary.

No dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide.

No dose adjustment is necessary for warfarin when administered with febuxostat. Administration of febuxostat (80 mg or 120 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy subjects. INR and Factor VII activity were also not affected by the co-administration of febuxostat.

Desipramine/CYP2D6 substrates
Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in healthy subjects, 120 mg ADENURIC QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme in vivo. Thus, co-administration of febuxostat with other CYP2D6 substrates is not expected to require any dose adjustment for those compounds.

Antacids
Concomitant ingestion of an antacid containing magnesium hydroxide and aluminium hydroxide has been shown to delay absorption of febuxostat (approximately 1 hour) and to cause a 32% decrease in Cmax, but no significant change in AUC was observed. Therefore, febuxostat may be taken without regard to antacid use.

4.6 Fertility, pregnancy and lactation

Pregnancy
Data on a very limited number of exposed pregnancies have not indicated any adverse effects of febuxostat on pregnancy or on the health of the foetus/new born child. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development or parturition (see section 5.3). The potential risk for human is unknown. Febuxostat should not be used during pregnancy.

Breastfeeding
It is unknown whether febuxostat is excreted in human breast milk. Animal studies have shown excretion of this active substance in breast milk and an impaired development of suckling pups. A risk to a suckling infant cannot be excluded. Febuxostat should not be used while breastfeeding.

Fertility
In animals, reproduction studies up to 48 mg/kg/day showed no dose-dependent adverse effects on fertility (see section 5.3). The effect of ADENURIC on human fertility is unknown.

4.7 Effects on ability to drive and use machines

Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of Febuxostat. Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that ADENURIC does not adversely affect performance.

4.8 Undesirable effects

Summary of the safety profile
The most commonly reported adverse reactions in clinical trials (4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience in gout patients are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema. These adverse reactions were
mostly mild or moderate in severity. Rare serious hypersensitivity reactions to febuxostat, some of which were associated to systemic symptoms, have occurred in the post-marketing experience.

Tabulated list of adverse reactions
Common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100) and rare (≥1/10,000 to <1/1,000) adverse reactions occurring in patients treated with febuxostat are listed below. The frequencies are based on studies and post-marketing experience in gout patients.

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 1: Adverse reactions in combined phase 3, long-term extension studies and post-marketing experience in gout patients.

<table>
<thead>
<tr>
<th>Category</th>
<th>Frequency</th>
<th>Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Rare</td>
<td>Pancytopenia, thrombocytopenia, agranulocytosis*</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Rare</td>
<td>Anaphylactic reaction*, drug hypersensitivity*</td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td>Uncommon</td>
<td>Blood thyroid stimulating hormone increased</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Rare</td>
<td>Blurred vision</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Common***</td>
<td>Gout flares</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Diabetes mellitus, hyperlipidemia, decrease appetite, weight increase</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Weight decrease, increase appetite, anorexia</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Uncommon</td>
<td>Libido decreased, insomnia</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Nervousness</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Common</td>
<td>Headache</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Dizziness, paraesthesia, hemiparesis, somnolence, altered taste, hypoaesthesia, hyposmia</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>Rare</td>
<td>Tinnitus</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Uncommon</td>
<td>Atrial fibrillation, palpitations, ECG abnormal, left bundle branch block (see section Tumor Lysis Syndrome), sinus tachycardia (see section Tumor Lysis Syndrome)</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Uncommon</td>
<td>Hypertension, flushing, hot flush, haemorrhage (see section Tumor Lysis Syndrome)</td>
</tr>
<tr>
<td>Respiratory system disorders</td>
<td>Uncommon</td>
<td>Dyspnoea, bronchitis, upper respiratory tract infection, cough</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Common</td>
<td>Diarrhoea**, nausea</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Abdominal pain, abdominal distension, gastro-oesophageal reflux disease, vomiting, dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Pancreatitis, mouth ulceration</td>
</tr>
<tr>
<td>Hepato-biliary disorders</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Common</td>
<td>Rash (including various types of rash reported with lower frequencies, see below)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>--------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Dermatitis, urticaria, pruritus, skin discolouration, skin lesion, petechiae, rash macular, rash maculopapular, rash papular</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Toxic epidermal necrolysis*, Stevens-Johnson Syndrome*, angioedema*, drug reaction with eosinophilia and systemic symptoms*, generalized rash (serious)<em>, erythema, exfoliative rash, rash follicular, rash vesicular, rash pustular, rash pruritic</em>, rash erythematous, rash morbilliform, alopecia, hyperhidrosis</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Uncommon</td>
<td>Arthralgia, arthritis, myalgia, musculoskeletal pain, muscle weakness, muscle spasm, muscle tightness, bursitis</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Rhabdomyolysis*, joint stiffness, musculoskeletal stiffness</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Uncommon</td>
<td>Renal failure, nephrolithiasis, haematuria, pollakiuria, proteinuria</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Tubulointerstitial nephritis*, micturition urgency</td>
</tr>
<tr>
<td>Reproductive system and breast disorder</td>
<td>Uncommon</td>
<td>Erectile dysfunction</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Common</td>
<td>Oedema</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Fatigue, chest pain, chest discomfort</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Thirst</td>
</tr>
<tr>
<td>Investigations</td>
<td>Uncommon</td>
<td>Blood amylase increase, platelet count decrease, WBC decrease, lymphocyte count decrease, blood creatinine increase, blood creatinine increase, haemoglobin decrease, blood urea increase, blood triglycerides increase, blood cholesterol increase, haematocrit decrease, blood lactate dehydrogenase increased, blood potassium increase</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Blood glucose increased, activated partial thromboplastin time prolonged, red blood cell count decrease, blood alkaline phosphatase increase, blood creatine phosphokinase increase*</td>
</tr>
</tbody>
</table>

* Adverse reactions coming from post-marketing experience
** Treatment-emergent non-infective diarrhoea and abnormal liver function tests in the combined Phase 3 studies are more frequent in patients concomitantly treated with colchicine.
*** See section 5.1 for incidences of gout flares in the individual Phase 3 randomized controlled studies.

**Description of selected adverse reactions**

Rare serious hypersensitivity reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal necrolysis and anaphylactic reaction/shock, have occurred in the post-marketing experience. Stevens-Johnson Syndrome and Toxic epidermal necrolysis are characterised by progressive skin rashes associated with blisters or mucosal lesions and eye irritation. Hypersensitivity reactions to febuxostat can be associated to the following symptoms: skin reactions characterised by infiltrated
maculopapular eruption, generalised or exfoliative rashes, but also skin lesions, facial oedema, fever, haematologic abnormalities such as thrombocytopenia and eosinophilia, and single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis) (see section 4.4). Gout flares were commonly observed soon after the start of treatment and during the first months. Thereafter, the frequency of gout flare decreases in a time-dependent manner. Gout flare prophylaxis is recommended (see section 4.2 and 4.4).

Tumor Lysis Syndrome

Summary of the safety profile

In the randomized, double-blind, Phase 3 pivotal FLORENCE (FLO-01) study comparing febuxostat with allopurinol (346 patients undergoing chemotherapy for haematologic malignancies and at intermediate-to-high risk of TLS), only 22 (6.4%) patients overall experienced adverse reactions, namely 11 (6.4%) patients in each treatment group. The majority of adverse reactions were either mild or moderate. Overall, the FLORENCE trial did not highlight any particular safety concern in addition to the previous experience with ADENURIC in gout, with the exception of the following three adverse reactions (listed above in table 1).

Cardiac disorders:
Uncommon: Left bundle branch block, sinus tachycardia

Vascular disorders:
Uncommon: haemorrhage

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Patients with an overdose should be managed by symptomatic and supportive care.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antigout preparation, preparations inhibiting uric acid production, ATC code: M04AA03

Mechanism of action

Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. Febuxostat is a potent, non-purine selective inhibitor of XO (NP-SIXO) with an \textit{in vitro} inhibition Ki value less than one nanomolar. Febuxostat has been shown to potently inhibit both the oxidized and reduced forms of XO. At therapeutic concentrations febuxostat does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.

Clinical efficacy and safety

\textit{Gout}
The efficacy of ADENURIC was demonstrated in three Phase 3 pivotal studies (the two pivotal APEX and FACT studies, and the additional CONFIRMS study, described below) that were conducted in 4101 patients with hyperuricaemia and gout. In each phase 3 pivotal study, ADENURIC demonstrated superior ability to lower and maintain serum uric acid levels compared to allopurinol. The primary efficacy endpoint in the APEX and FACT studies was the proportion of patients whose last 3 monthly serum uric acid levels were < 6.0 mg/dL (357 µmol/L). In the additional phase 3 CONFIRMS study, for which results became available after the marketing authorisation for ADENURIC was first issued, the primary efficacy endpoint was the proportion of patients whose serum urate level was < 6.0 mg/dL at the final visit. No patients with organ transplant have been included in these studies (see section 4.2).

APEX Study: The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study. One thousand and seventy-two (1072) patients were randomized: placebo (n=134), ADENURIC 80 mg QD (n=267), ADENURIC 120 mg QD (n=269), ADENURIC 240 mg QD (n=134) or allopurinol (300 mg QD [n=258] for patients with a baseline serum creatinine ≤1.5 mg/dL or 100 mg QD [n=10] for patients with a baseline serum creatinine >1.5 mg/dL and ≤2.0 mg/dL). Two hundred and forty mg febuxostat (2 times the recommended highest dose) was used as a safety evaluation dose.

The APEX study showed statistically significant superiority of both the ADENURIC 80 mg QD and the ADENURIC 120 mg QD treatment arms versus the conventionally used doses of allopurinol 300 mg (n = 258) /100 mg (n = 10) treatment arm in reducing the sUA below 6 mg/dL (357 µmol/L) (see Table 2 and Figure 1).

FACT Study: The Febuxostat Allopurinol Controlled Trial (FACT) Study was a Phase 3, randomized, double-blind, multicenter, 52-week study. Seven hundred sixty (760) patients were randomized: ADENURIC 80 mg QD (n=256), ADENURIC 120 mg QD (n=251), or allopurinol 300 mg QD (n=253).

The FACT study showed the statistically significant superiority of both ADENURIC 80 mg and ADENURIC 120 mg QD treatment arms versus the conventionally used dose of allopurinol 300 mg treatment arm in reducing and maintaining sUA below 6 mg/dL (357 µmol/L).

Table 2 summarises the primary efficacy endpoint results:

<table>
<thead>
<tr>
<th>Study</th>
<th>ADENURIC 80 mg QD</th>
<th>ADENURIC 120 mg QD</th>
<th>Allopurinol 300 / 100 mg QD¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>APEX (28 weeks)</td>
<td>48% (n=262)</td>
<td>65%* # (n=269)</td>
<td>22% (n=268)</td>
</tr>
<tr>
<td>FACT (52 weeks)</td>
<td>53% (n=255)</td>
<td>62% (n=250)</td>
<td>21% (n=251)</td>
</tr>
<tr>
<td>Combined Results</td>
<td>51% (n=517)</td>
<td>63%* # (n=519)</td>
<td>22% (n=519)</td>
</tr>
</tbody>
</table>

¹ results from subjects receiving either 100 mg QD (n=10): patients with serum creatinine >1.5 and ≤2.0 mg/dL or 300 mg QD (n=509) were pooled for analyses.

* p < 0.001 vs allopurinol, # p < 0.001 vs 80 mg

The ability of ADENURIC to lower serum uric acid levels was prompt and persistent. Reduction in serum uric acid level to <6.0 mg/dL (357 µmol/L) was noted by the Week 2 visit and was maintained throughout treatment. The mean serum uric acid levels over time for each treatment group from the two pivotal Phase 3 studies are shown in Figure 1.
Figure 1 Mean Serum Uric Acid Levels in Combined Pivotal Phase 3 Studies

Note: 509 patients received allopurinol 300 mg QD; 10 patients with serum creatinine >1.5 and ≤2.0 mg/dL were dosed with 100 mg QD. (10 patients out of 268 in APEX study).

240 mg febuxostat was used to evaluate the safety of febuxostat at twice the recommended highest dose.

CONFIRMS Study: The CONFIRMS study was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and efficacy of febuxostat 40 mg and 80 mg, in comparison with allopurinol 300 mg or 200 mg, in patients with gout and hyperuricaemia. Two thousand and two hundred-sixty nine (2269) patients were randomized: ADENURIC 40 mg QD (n=757), ADENURIC 80 mg QD (n=756), or allopurinol 300/200 mg QD (n=756). At least 65% of the patients had mild-moderate renal impairment (with creatinine clearance of 30-89 mL/min). Prophylaxis against gout flares was obligatory over the 26-week period.

The proportion of patients with serum urate levels of < 6.0 mg/dL (357 µmol/L) at the final visit, was 45% for 40 mg febuxostat, 67% for febuxostat 80 mg and 42% for allopurinol 300/200 mg, respectively.

Primary endpoint in the sub-group of patients with renal impairment

The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine > 1.5 mg/dL and ≤2.0 mg/dL). For renally impaired subjects who were randomized to allopurinol, the dose was capped at 100 mg QD. ADENURIC achieved the primary efficacy endpoint in 44% (80 mg QD), 45% (120 mg QD), and 60% (240 mg QD) of patients compared to 0% in the allopurinol 100 mg QD and placebo groups.

There were no clinically significant differences in the percent decrease in serum uric acid concentration in healthy subjects irrespective of their renal function (58% in the normal renal function group and 55% in the severe renal dysfunction group).

An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study, and showed that febuxostat was significantly more efficacious in lowering serum urate levels to < 6 mg/dL compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65% of patients studied).

Primary endpoint in the sub group of patients with sUA ≥ 10 mg/dL
Approximately 40% of patients (combined APEX and FACT) had a baseline sUA of ≥ 10 mg/dL. In this subgroup ADENURIC achieved the primary efficacy endpoint (sUA < 6.0 mg/dL at the last 3 visits) in 41% (80 mg QD), 48% (120 mg QD), and 66% (240 mg QD) of patients compared to 9% in the allopurinol 300 mg/100 mg QD and 0% in the placebo groups.

In the CONFIRMS study, the proportion of patients achieving the primary efficacy endpoint (sUA < 6.0 mg/dL at the final visit) for patients with a baseline serum urate level of ≥ 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD 49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively.

Clinical Outcomes: proportion of patients requiring treatment for a gout flare

APEX study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for gout flare compared to febuxostat 80 mg (28%), allopurinol 300 mg (23%) and placebo (20%). Flares increased following the prophylaxis period and gradually decreased over time. Between 46% and 55% of subjects received treatment for gout flares from Week 8 and Week 28. Gout flares during the last 4 weeks of the study (Weeks 24-28) were observed in 15% (febuxostat 80, 120 mg), 14% (allopurinol 300 mg) and 20% (placebo) of subjects.

FACT study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for a gout flare compared to both the febuxostat 80 mg (22%) and allopurinol 300 mg (21%) treatment groups. After the 8-week prophylaxis period, the incidences of flares increased and gradually decreased over time (64% and 70% of subjects received treatment for gout flares from Week 8-52). Gout flares during the last 4 weeks of the study (Weeks 49-52) were observed in 6-8% (febuxostat 80 mg, 120 mg) and 11% (allopurinol 300 mg) of subjects.

The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level <6.0 mg/dL, <5.0 mg/dL, or <4.0 mg/dL compared to the group that achieved an average post-baseline serum urate level ≥6.0 mg/dL during the last 32 weeks of the treatment period (Week 20-Week 24 to Week 49 - 52 intervals).

During the CONFIRMS study, the percentages of patients who required treatment for gout flares (Day 1 through Month 6) were 31% and 25% for the febuxostat 80 mg and allopurinol groups, respectively. No difference in the proportion of patients requiring treatment for gout flares was observed between the febuxostat 80 mg and 40 mg groups.

Long-term, open label extension Studies

EXCEL Study (C02-021): The Excel study was a three years Phase 3, open label, multicenter, randomised, allopurinol-controlled, safety extension study for patients who had completed the pivotal Phase 3 studies (APEX or FACT). A total of 1,086 patients were enrolled: ADENURIC 80 mg QD (n=649), Adenuric 120 mg QD (n=292) and allopurinol 300/100 mg QD (n=145). About 69% of patients required no treatment change to achieve a final stable treatment. Patients who had 3 consecutive sUA levels >6.0 mg/dL were withdrawn. Serum urate levels were maintained over time (i.e. 91% and 93% of patients on initial treatment with febuxostat 80 mg and 120 mg, respectively, had sUA <6 mg/dL at Month 36).

Three years data showed a decrease in the incidence of gout flares with less than 4% of patients requiring treatment for a flare (i.e. more than 96% of patients did not require treatment for a flare) at Month 16-24 and at Month 30-36.

46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.

FOCUS Study (TMX-01-005) was a 5 years Phase 2, open-label, multicenter, safety extension study for patients who had completed the febuxostat 4 weeks of double blind dosing in study TMX-00-004. 116 patients were enrolled and received initially febuxostat 80 mg QD. 62% of patients required no
Dose adjustment to maintain sUA <6 mg/dL and 38% of patients required a dose adjustment to achieve a final stable dose.

The proportion of patients with serum urate levels of <6.0 mg/dL (357 µmol/L) at the final visit was greater than 80% (81-100%) at each febuxostat dose.

During the phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). These rates were similar to the rates reported on allopurinol (4.2%) (see section 4.4). Increased TSH values (>5.5 µIU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) and patients with allopurinol (5.8%) in the long term open label extension studies (see section 4.4).

**Tumor Lysis Syndrome**

The efficacy and safety of ADENURIC in the prevention and treatment of Tumor Lysis Syndrome was evaluated in the FLORENCE (FLO-01) study. ADENURIC showed a superior and faster urate lowering activity compared to allopurinol. FLORENCE was a randomized (1:1), double blind, phase III, pivotal trial comparing ADENURIC 120 mg once daily with allopurinol 200 to 600 mg daily (mean allopurinol daily dose [± standard deviation]: 349.7 ± 112.90 mg) in terms of control of serum uric acid level. Eligible patients had to be candidates for allopurinol treatment or have no access to rasburicase. Primary endpoints were serum uric acid area under the curve (AUC sUA<sub>1.8</sub>) and change in serum creatinine (sC) level both from baseline to Day 8.

Overall, 346 patients with haematological malignancies undergoing chemotherapy and at intermediate / high risk of Tumor Lysis Syndrome were included. Mean AUC sUA<sub>1.8</sub> (mgxh/dl) was significantly lower with ADENURIC (514.0 ± 225.71 vs 708.0 ± 234.42; least square means difference: -196.794 [95% confidence interval: -238.600 ; -154.988]; p < .0001). Furthermore, the mean serum uric acid level was significantly lower with ADENURIC since the first 24 hours of treatment and at any following time point. No significant difference in mean serum creatinine change (%) occurred between ADENURIC and allopurinol (-0.83 ± 26.98 vs -4.92 ± 16.70 respectively; least square means difference: 4.0970 [95% confidence interval: -0.6467 ; 8.8406]; p=0.0903). With regard to secondary endpoints, no significant difference was detected in terms of incidence of laboratory TLS (8.1% and 9.2% in ADENURIC and allopurinol arm, respectively; relative risk: 0.915 [95% confidence interval: 0.4408 ; 1.7369]; p=0.8488) nor of clinical TLS (1.7% and 1.2% in ADENURIC and allopurinol arm, respectively; relative risk: 0.994 [95% confidence interval: 0.9691 ; 1.0199]; p=1.0000). Incidence of overall treatment-emergent signs and symptoms and adverse drug reactions was 67.6% vs 64.7% and 6.4% vs 6.4% with ADENURIC and allopurinol respectively. In the FLORENCE study ADENURIC demonstrated a superior control of serum uric acid level compared to allopurinol in patients scheduled to receive the latter drug. No data comparing ADENURIC with rasburicase are currently available. The efficacy and safety of febuxostat has not been established in patients with acute severe TLS, e.g. in patients who failed on other urate lowering therapies.

### 5.2 Pharmacokinetic properties

In healthy subjects, maximum plasma concentrations (C<sub>max</sub>) and area under the plasma concentration time curve (AUC) of febuxostat increased in a dose proportional manner following single and multiple doses of 10 mg to 120 mg. For doses between 120 mg and 300 mg, a greater than dose proportional increase in AUC is observed for febuxostat. There is no appreciable accumulation when doses of 10 mg to 240 mg are administered every 24 hours. Febuxostat has an apparent mean terminal elimination half-life (t<sub>1/2</sub>) of approximately 5 to 8 hours.

Population pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with hyperuricaemia and gout, treated with ADENURIC 40-240 mg QD. In general, febuxostat pharmacokinetic parameters estimated by these analyses are consistent with those obtained from healthy subjects, indicating that healthy subjects are representative for pharmacokinetic/pharmacodynamic assessment in the patient population with gout.
Absorption
Febuxostat is rapidly (t\text{max} of 1.0-1.5 h) and well absorbed (at least 84%). After single or multiple oral 80 and 120 mg once daily doses, C\text{max} is approximately 2.8-3.2 µg/mL, and 5.0-5.3 µg/mL, respectively. Absolute bioavailability of the febuxostat tablet formulation has not been studied.

Following multiple oral 80 mg once daily doses or a single 120 mg dose with a high fat meal, there was a 49% and 38% decrease in C\text{max} and a 18% and 16% decrease in AUC, respectively. However, no clinically significant change in the percent decrease in serum uric acid concentration was observed where tested (80 mg multiple dose). Thus, ADENURIC may be taken without regard to food.

Distribution
The apparent steady state volume of distribution (V\text{ss/F}) of febuxostat ranges from 29 to 75 L after oral doses of 10-300 mg. The plasma protein binding of febuxostat is approximately 99.2%, (primarily to albumin), and is constant over the concentration range achieved with 80 and 120 mg doses. Plasma protein binding of the active metabolites ranges from about 82% to 91%.

Biotransformation
Febuxostat is extensively metabolized by conjugation via uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system and oxidation via the cytochrome P450 (CYP) system. Four pharmacologically active hydroxyl metabolites have been identified, of which three occur in plasma of humans. \textit{In vitro} studies with human liver microsomes showed that those oxidative metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was formed mainly by UGT 1A1, 1A8, and 1A9.

Elimination
Febuxostat is eliminated by both hepatic and renal pathways. Following an 80 mg oral dose of $^{14}$C-labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%). In addition to the urinary excretion, approximately 45% of the dose was recovered in the faeces as the unchanged febuxostat (12%), the acyl glucuronide of the active substance (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%).

Renal impairment
Following multiple doses of 80 mg of ADENURIC in patients with mild, moderate or severe renal impairment, the C\text{max} of febuxostat did not change, relative to subjects with normal renal function. The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5 µg·h/mL in the normal renal function group to 13.2 µg·h/mL in the severe renal dysfunction group. The C\text{max} and AUC of active metabolites increased up to 2- and 4-fold, respectively. However, no dose adjustment is necessary in patients with mild or moderate renal impairment.

Hepatic impairment
Following multiple doses of 80 mg of ADENURIC in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, the C\text{max} and AUC of febuxostat and its metabolites did not change significantly compared to subjects with normal hepatic function. No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C).

Age
There were no significant changes observed in AUC of febuxostat or its metabolites following multiple oral doses of ADENURIC in elderly as compared to younger healthy subjects.

Gender
Following multiple oral doses of ADENURIC, the C\text{max} and AUC were 24% and 12% higher in females than in males, respectively. However, weight-corrected C\text{max} and AUC were similar between the genders. No dose adjustment is needed based on gender.
5.3 Preclinical safety data

Effects in non-clinical studies were generally observed at exposures in excess of the maximum human exposure.

Pharmacokinetic modelling and simulation of rat data suggests that, when co-administered with febuxostat, the clinical dose of mercaptopurine/azathioprine should be reduced to 20% or less of the previously prescribed dose in order to avoid possible haematological effects (see section 4.4 and 4.5).

Carcinogenesis, mutagenesis, impairment of fertility
In male rats, a statistically significant increase in urinary bladder tumours (transitional cell papilloma and carcinoma) was found only in association with xanthine calculi in the high dose group, at approximately 11 times human exposure. There was no significant increase in any other tumour type in either male or female mice or rats. These findings are considered a consequence of species specific purine metabolism and urine composition and of no relevance to clinical use.

A standard battery of test for genotoxicity did not reveal any biologically relevant genotoxic effects for febuxostat.

Febuxostat at oral doses up to 48 mg/kg/day was found to have no effect on fertility and reproductive performance of male and female rats.

There was no evidence of impaired fertility, teratogenic effects, or harm to the foetus due to febuxostat. There was high dose maternal toxicity accompanied by a reduction in weaning index and reduced development of offspring in rats at approximately 4.3 times human exposure. Teratology studies, performed in pregnant rats at approximately 4.3 times and pregnant rabbits at approximately 13 times human exposure did not reveal any teratogenic effects.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Lactose monohydrate
Microcrystalline cellulose
Magnesium stearate
Hydroxypropylcellulose
Croscarmellose sodium
Silica, colloidal hydrated

Tablet coating
Opadry II, Yellow, 85F42129 containing:
Polyvinyl alcohol
Titanium dioxide (E171)
Macrogols 3350
Talc
Iron oxide yellow (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life
3 years.

6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container
Clear (Aclar/PVC/Aluminium or PVC/PE/PVDC/Aluminium) blister of 14 tablets.
ADENURIC 120 mg is available in pack sizes of 14, 28, 42, 56, 84 and 98 film-coated tablets.
Not all pack sizes may be marketed.

6.6 Special precautions for disposal
No special requirements.

7. MARKETING AUTHORISATION HOLDER
Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare, L-1611 Luxembourg

8. MARKETING AUTHORISATION NUMBER(S)
EU/1/08/447/003
EU/1/08/447/004
EU/1/08/447/009
EU/1/08/447/010
EU/1/08/447/011
EU/1/08/447/012
EU/1/08/447/019
EU/1/08/447/020
EU/1/08/447/021
EU/1/08/447/022
EU/1/08/447/023
EU/1/08/447/024

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 21 April 2008
Date of latest renewal: 20 December 2012

10. DATE OF REVISION OF THE TEXT
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURE(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Patheon France
40 Boulevard de Champaret
FR-38300 Bourgoin Jallieu
France

or

Menarini - Von Heyden GmbH
Leipziger Strasse 7-13
01097 Dresden
Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

• Periodic Safety Update Reports
  The requirements for submission of periodic safety updated reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk Management Plan (RMP)
  The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
  • At the request of the European Medicine Agency;
  • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON BOX

#### 1. NAME OF THE MEDICINAL PRODUCT

ADENURIC 80 mg film-coated tablets
Febuxostat

#### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 80 mg febuxostat.

#### 3. LIST OF EXCIPIENTS

Also contains lactose (as monohydrate).
See the package leaflet for further information.

#### 4. PHARMACEUTICAL FORM AND CONTENTS

- 14 film-coated tablets
- 28 film-coated tablets
- 42 film-coated tablets
- 56 film-coated tablets
- 84 film-coated tablets
- 98 film-coated tablets

#### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use.
Read the package leaflet before use.

#### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

#### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

#### 8. EXPIRY DATE

EXP

#### 9. SPECIAL STORAGE CONDITIONS

#### 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Marketing Authorisation Holder:  
Menarini International O. L. S.A.  
1, Avenue de la Gare, L-1611 Luxembourg  
Luxembourg

12. **MARKETING AUTHORISATION NUMBER(S)**

- EU/1/08/447/001 28 film-coated tablets  
- EU/1/08/447/002 84 film-coated tablets  
- EU/1/08/447/005 14 film-coated tablets  
- EU/1/08/447/006 42 film-coated tablets  
- EU/1/08/447/007 56 film-coated tablets  
- EU/1/08/447/008 98 film-coated tablets  
- EU/1/08/447/013 14 film-coated tablets  
- EU/1/08/447/014 28 film-coated tablets  
- EU/1/08/447/015 42 film-coated tablets  
- EU/1/08/447/016 56 film-coated tablets  
- EU/1/08/447/017 84 film-coated tablets  
- EU/1/08/447/018 98 film-coated tablets

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

ADENURIC 80 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC: {number}  
SN: {number}  
NN: {number}
**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**
PVC/ACLAR/ALUMINIUM OR PVC/PE/PVDC/ALUMINIUM BLISTER

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
<td></td>
</tr>
</tbody>
</table>
|   | ADENURIC 80 mg tablets  
Febuxostat |
| **2. NAME OF THE MARKETING AUTHORISATION HOLDER** |   |
|   | Menarini International O. L. S.A. |
| **3. EXPIRY DATE** |   |
|   | EXP |
| **4. BATCH NUMBER** |   |
|   | Lot |
| **5. OTHER** | Mon  
Tue  
Wed  
Thu  
Fri  
Sat  
Sun |
1. **NAME OF THE MEDICINAL PRODUCT**

ADENURIC 120 mg film-coated tablets
Febuxostat

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 120 mg febuxostat.

3. **LIST OF EXCIPIENTS**

Also contains lactose (as monohydrate).
See the package leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**

- 14 film-coated tablets
- 28 film-coated tablets
- 42 film-coated tablets
- 56 film-coated tablets
- 84 film-coated tablets
- 98 film-coated tablets

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

For oral use.
Read the package leaflet before use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHOURISATION HOLDER

Marketing Authorisation Holder:
Menarini International O. L. S.A.
1, Avenue de la Gare, L-1611 Luxembourg
Luxembourg

12. MARKETING AUTHOURISATION NUMBER(S)

EU/1/08/447/003 28 film-coated tablets
EU/1/08/447/004 84 film-coated tablets
EU/1/08/447/009 14 film-coated tablets
EU/1/08/447/010 42 film-coated tablets
EU/1/08/447/011 56 film-coated tablets
EU/1/08/447/012 98 film-coated tablets
EU/1/08/447/019 14 film-coated tablets
EU/1/08/447/020 28 film-coated tablets
EU/1/08/447/021 42 film-coated tablets
EU/1/08/447/022 56 film-coated tablets
EU/1/08/447/023 84 film-coated tablets
EU/1/08/447/024 98 film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

ADENURIC 120 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC: {number}
SN: {number}
NN: {number}
<table>
<thead>
<tr>
<th>Minimum Particulars to Appear on Blisters or Strips</th>
</tr>
</thead>
<tbody>
<tr>
<td>PVC/ACLAR/ALUMINIUM OR PVC/PE/PVDC/ALUMINIUM BLISTER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. Name of the Medicinal Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADENURIC 120 mg tablets</td>
</tr>
<tr>
<td>Febuxostat</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Name of the Marketing Authorisation Holder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menarini International O. L. S.A.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Batch Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mon</td>
</tr>
<tr>
<td>Tue</td>
</tr>
<tr>
<td>Wed</td>
</tr>
<tr>
<td>Thu</td>
</tr>
<tr>
<td>Fri</td>
</tr>
<tr>
<td>Sat</td>
</tr>
<tr>
<td>Sun</td>
</tr>
</tbody>
</table>
B. PACKAGE LEAFLET
1. What ADENURIC is and what it is used for

ADENURIC tablets contain the active substance febuxostat and are used to treat gout, which is associated with an excess of a chemical called uric acid (urate) in the body. In some people, the amount of uric acid builds up in the blood and may become too high to remain soluble. When this happens, urate crystals may form in and around the joints and kidneys. These crystals can cause sudden, severe pain, redness, warmth and swelling in a joint (known as a gout attack). Left untreated, larger deposits called tophi may form in and around joints. These tophi may cause joint and bone damage.

ADENURIC works by reducing uric acid levels. Keeping uric acid levels low by taking ADENURIC once every day stops crystals building up, and over time it reduces symptoms. Keeping uric acid levels sufficiently low for a long enough period can also shrink tophi.

ADENURIC 120 mg tablets is also used to treat and prevent high blood levels of uric acid that may occur when you start to receive chemotherapy for blood cancers. When chemotherapy is given, cancer cells are destroyed, and uric acid levels increase in the blood accordingly, unless the formation of uric acid is prevented.

ADENURIC is for adults.

2. What you need to know before you take ADENURIC

Do not take ADENURIC

- If you are allergic to febuxostat or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions

Talk to your doctor before taking ADENURIC:

- If you have or have had heart failure or heart problems
- If you have or have had renal disease and/or serious allergic reaction to Allopurinol (a medication used for the treatment of Gout)
- If you have or have had liver disease or liver function test abnormalities
- If you are being treated for high uric acid levels as a result of Lesch-Nyhan syndrome (a rare inherited condition in which there is too much uric acid in the blood)
- If you have thyroid problems.

Should you experience allergic reactions to ADENURIC, stop taking this medicine (see also section 4). Possible symptoms of allergic reactions might be:
- rash including severe forms (e.g. blisters, nodules, itchy-, exfoliative rash), itchiness
- swelling of limbs or face
- difficulties in breathing
- fever with enlarged lymph nodes
- but also serious life threatening allergic conditions with cardiac and circulatory arrest.

Your doctor might decide to permanently stop treatment with ADENURIC.

There have been rare reports of potentially life-threatening skin rashes (Stevens-Johnson Syndrome) with the use of ADENURIC, appearing initially as reddish target-like spots or circular patches often with central blister on the trunk. It may also include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). The rash may progress to widespread blistering or peeling of the skin.

If you have developed Stevens-Johnson Syndrome with the use of febuxostat, you must not be restarted on ADENURIC at any time. If you develop a rash or these skin symptoms, seek immediate advice from a doctor and tell that you are taking this medicine.

If you are having a gout attack at the moment (a sudden onset of severe pain, tenderness, redness, warmth and swelling in a joint), wait for the gout attack to subside before first starting treatment with ADENURIC.

For some people, gout attacks may flare up when starting certain medicines that control uric acid levels. Not everyone gets flares, but you could get a flare-up even if you are taking ADENURIC, and especially during the first weeks or months of treatment. It is important to keep taking ADENURIC even if you have a flare, as ADENURIC is still working to lower uric acid. Over time, gout flares will occur less often and be less painful if you keep taking ADENURIC every day.

Your doctor will often prescribe other medicines, if they are needed, to help prevent or treat the symptoms of flares (such as pain and swelling in a joint).

In patients with very high urate levels (e.g. those undergoing cancer chemotherapy), treatment with uric acid-lowering medicines could lead to the build-up of xanthine in the urinary tract, with possible stones, even though this has not been observed in patients being treated with ADENURIC for Tumor Lysis Syndrome.

Your doctor may ask you to have blood tests to check that your liver is working normally.

Children and adolescents

Do not give this medicine to children under the age of 18 because the safety and efficacy have not been established.
Other medicines and ADENURIC

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. It is especially important to tell your doctor or pharmacist if you are taking medicines containing any of the following substances as they may interact with ADENURIC and your doctor may wish to consider necessary measures:

- Mercaptopurine (used to treat cancer)
- Azathioprine (used to reduce immune response)
- Theophylline (used to treat asthma)

Pregnancy and breast-feeding

It is not known if ADENURIC may harm your unborn child. ADENURIC should not be used during pregnancy. It is not known if ADENURIC may pass into human breast milk. You should not use ADENURIC if you are breast feeding, or if you are planning to breastfeed.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines

Be aware that you may experience dizziness, sleepiness, blurred vision and numbness or tingling sensation during treatment and should not drive or operate machines if affected.

ADENURIC contains lactose

ADENURIC tablets contain lactose (a type of sugar). If you have been told that you have an intolerance to some sugars contact your doctor before taking this medicine.

3. How to take ADENURIC

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

- The usual dose is one tablet daily. The back of the blister pack is marked with the days of the week to help you check that you have taken a dose each day.
- The tablets should be taken by mouth and can be taken with or without food.

Gout

ADENURIC is available as either an 80 mg tablet or a 120 mg tablet. Your doctor will have prescribed the strength most suitable for you.

Continue to take ADENURIC every day even when you are not experiencing gout flare or attack.

Prevention and treatment of high uric acid levels in patients undergoing cancer chemotherapy

ADENURIC is available as a 120 mg tablet.

Start taking ADENURIC two days before chemotherapy and continue its use according to your doctor’s advice. Usually treatment is short-term.

If you take more ADENURIC than you should

In the event of an accidental overdose ask your doctor what to do, or contact your nearest accident and emergency department.
If you forget to take ADENURIC

If you miss a dose of ADENURIC take it as soon as you remember unless it is almost time for your next dose, in which case miss out the forgotten dose and take your next dose at the normal time. Do not take a double dose to make up for a forgotten dose.

If you stop taking ADENURIC

Do not stop taking ADENURIC without the advice of your doctor even if you feel better. If you stop taking ADENURIC your uric acid levels may begin to rise and your symptoms may worsen due to the formation of new crystals of urate in and around your joints and kidneys.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop taking this medicine and contact your doctor immediately or go to an emergency department nearby if the following rare (may affect up to 1 in 1,000 people) side effects occur, because a serious allergic reaction might follow:

- anaphylactic reactions, drug hypersensitivity (see also section 2 “Warnings and precautions”)
- potentially life-threatening skin rashes characterised by formation of blisters and shedding of the skin and inner surfaces of body cavities, e.g. mouth and genitals, painful ulcers in the mouth and/or genital areas, accompanied by fever, sore throat and fatigue (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis), or by enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white-cells count in the blood (drug reaction with eosinophilia and systemic symptoms-DRESS) (see section 2)
- generalised skin rashes

The common side effects (may affect up to 1 in 10 people) are:

- abnormal liver test results
- diarrhoea
- headache
- rash (including various types of rash, please see below under “uncommon” and “rare” sections)
- nausea
- increase in gout symptoms
- localised swelling due to retention of fluids in tissues (oedema)

Other side effects which are not mentioned above are listed below.

Uncommon side effects (may affect up to 1 in 100 people) are:

- decreased appetite, change in blood sugar levels (diabetes) of which a symptom may be excessive thirst, increased blood fat levels, weight increase
- loss of sex drive
- difficulty in sleeping, sleepiness
- dizziness, numbness, tingling, reduced or altered sensation (hypoesthesia, hemiparesis or paraesthesia), altered sense of taste, diminished sense of smell (hyposmia)
- abnormal ECG heart tracing, irregular or rapid heartbeats, feeling your heart beat (palpitation)
- hot flushes or flushing (e.g. redness of the face or neck), increased blood pressure, bleeding (hemorrhage, seen only in patients taking chemotherapy for blood disorders)
- cough, shortness of breath, chest discomfort or pain, inflammation of nasal passage and/or throat (upper respiratory tract infection), bronchitis
- dry mouth, abdominal pain/discomfort or wind, heartburn/indigestion, constipation, more frequent passing of stools, vomiting, stomach discomfort
• itching, hives, skin inflammation, skin discoloration, small red or purple spots on the skin, small, flat red spots on the skin, flat, red area on the skin that is covered with small confluent bumps, rash, areas of redness and spots on the skin, other type of skin conditions
• muscle cramp, muscle weakness, pain/ache in muscles/joints, bursitis or arthritis (inflammation of joints usually accompanied by pain, swelling and/or stiffness), pain in extremity, back pain, muscle spasm
• blood in the urine, abnormal frequent urination, abnormal urine tests (increased level of proteins in the urine), a reduction in the ability of the kidneys to function properly
• fatigue, chest pain, chest discomfort
• stones in the gallbladder or in bile ducts (cholelithiasis)
• increase in blood thyroid stimulating hormone (TSH) level
• changes in blood chemistry or amount of blood cells or platelets (abnormal blood test results)
• kidney stones
• erectile difficulties

**Rare side effects** (may affect up to 1 in 1,000 people) are:
• muscle damage, a condition which on rare occasions can be serious. It may cause muscle problems and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown. Contact your doctor immediately if you experience muscle pain, tenderness or weakness
• severe swelling of the deeper layers of the skin, especially around the lips, eyes, genitals, hands, feet or tongue, with possible sudden difficult breathing
• high fever in combination with measles-like skin rash, enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white-cells count in the blood (leukocytosis, with or without eosinophilia)
• reddening of the skin (erythema), rash in various types (e.g. itchy, with white spots, with blisters, with blisters containing pus, with shedding of the skin, measles-like rash), widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis (Stevens-Johnson Syndrome/Toxic epidermal necrolysis)
• nervousness
• feeling thirsty
• ringing in the ears
• blurred vision, change in vision
• hair loss
• mouth ulceration
• inflammation of the pancreas: common symptoms are abdominal pain, nausea and vomiting
• increased sweating
• weight decrease, increased appetite, uncontrolled loss of appetite (anorexia)
• muscle and/or joint stiffness
• abnormally low blood cell counts (white or red blood cells or platelets)
• urgent need to urinate
• changes or decrease in urine amount due to inflammation in the kidneys (tubulointerstitial nephritis)
• inflammation of the liver (hepatitis)
• yellowing of the skin (jaundice)
• liver damage
• increased level of creatine phosphokinase in blood (an indicator of muscle damage)

**Reporting of side effects**

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store ADENURIC**

- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the carton and the tablet blister foil after ‘EXP.’ The expiry date refers to the last day of that month.
- This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What ADENURIC contains**

The active substance is febuxostat. Each tablet contains 80 mg or 120 mg of febuxostat.

The other ingredients are:
- **Tablet core:** lactose monohydrate, microcrystalline cellulose, magnesium stearate, hydroxypropylcellulose, croscarmellose sodium, colloidal hydrated silica.
- **Film-coating:** Opadry II yellow, 85F42129 containing: polyvinyl alcohol, titanium dioxide (E171), macrogols 3350, talc, iron oxide yellow (E172)

**What ADENURIC looks like and contents of the pack**

ADENURIC film-coated tablets are pale yellow to yellow in colour and capsule shaped. The 80 mg film-coated tablets are marked on one side with ‘80’. The 120 mg film-coated tablets are marked on one side with ‘120’.

ADENURIC 80 mg and 120 mg is packed in clear (Aclar/PVC/Aluminium or PVC/PE/PVDC/Aluminium) blister of 14 tablets.

ADENURIC 80 mg and 120 mg is available in packs containing 14, 28, 42, 56, 84 and 98 film-coated tablets.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

**Marketing Authorisation Holder**
Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare, L-1611 Luxembourg

**Manufacturer**
Patheon France
40 boulevard de Champaret
38300 Bourgoin Jallieu
France

Or
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

**België/Belgique/Belgien**  
Menarini Benelux NV/SA  
Tél/Tel: +32 (0)2 721 4545

**България**  
“Берлин-Хеми/А. Менарини България” ЕООД  
tel.: +359 2 96 55 365

**Česká republika**  
Berlin-Chemie/A. Menarini Ceska republika s.r.o.  
Tel: +420 267 199 333

**Danmark**  
Pharmaprim AB  
Tlf: +468355933

**Deutschland**  
Berlin-Chemie AG  
Tel: +49 (0) 30 67070

**Eesti**  
OÜ Berlin-Chemie Menarini Eesti  
Tel: +372 667 5001

**Ελλάδα**  
MENARINI HELLAS AE  
Τηλ.: +30 210 8316111-13

**España**  
Laboratorios Menarini S.A.  
Tel: +34-93 462 88 00

**France**  
MENARINI France  
Tél: +33 (0)1 45 60 77 20

**Hrvatska**  
Berlin-Chemie Menarini Hrvatska d.o.o.  
Tel: + 385 1 4821 361

**Ireland**  
A. Menarini Pharmaceuticals Ireland Ltd  
Tel: +353 1 284 6744

**İstanbul**  
Menarini Turkey Ltd.  
Tel: +90 212 448 76 00

**İzlanda**  
Menarini Iceland  
Tel: +39 03 614 09 00

**İzlanda (Islandia)**  
Menarini Iceland  
Tel: +39 03 614 09 00

**İtalya**  
Servizio Clienti Menarini  
Tel: +39 03 614 09 00

**İzlanda (Islandia)**  
Menarini Iceland  
Tel: +39 03 614 09 00

**Luxembourg/Luxemburg**  
Menarini Benelux NV/SA  
Tel/Tel: +32 (0)2 721 4545

**Magyarország**  
Berlin-Chemie/A. Menarini Kft.  
Tel.: +36 23501301

**Malta**  
Menarini International Operations Luxembourg S.A.  
Tel: +352 264976

**Nederland**  
Menarini Benelux NV/SA  
Tel: +32 (0)2 721 4545

**Norge**  
Pharmaprim AB  
Tlf: +468355933

**Österreich**  
A. Menarini Pharma GmbH.  
Tel: +43 1 879 95 85-0

**Polska**  
Berlin-Chemie/Menarini Polska Sp. z o.o.  
Tel.: +48 22 566 21 00

**Portugal**  
A. Menarini Portugal – Farmacêutica, S.A.  
Tel: +351 210 935 500

**România**  
Berlin-Chemie A.Menarini S.R.L.  
Tel: +40 21 232 34 32

**Slovenija**  
Berlin-Chemie AG, Podružnica Ljubljana  
Tel: +386 01 300 2160
Ísland
Pharmaprim AB
Simi: +468355933

Italia
A. Menarini Industrie Farmaceutiche Riunite s.r.l.
Tel: +39-055 56801

Slovenská republika
Berlin-Chemie AG - obchodné zastúpenie v SR
Tel: +421 2 544 30 730

Suomi/Finland
Berlin-Chemie/A. Menarini Suomi OY
Puh/Tel: +358 403 000 760

Kύπρος
MENARINI HELLAS AE
Τηλ: +30 210 8316111-13

Sverige
Pharmaprim AB
Tel: +468355933

Latvija
SIA Berlin-Chemie/Menarini Baltic
Tel: +371 67103210

United Kingdom
A. Menarini Farmaceutica Internazionale S.R.L.
Tel: +44 (0)1628 856400

This leaflet was last revised in

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website